Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


05.08.2019

1 AJR Am J Roentgenol
2 Anticancer Res
1 Br J Radiol
1 Cancer Imaging
2 Clin Cancer Res
10 Eur Urol
1 Int J Radiat Oncol Biol Phys
2 Int J Urol
2 J Nucl Med
14 J Urol
1 Nat Rev Urol
1 Oncol Rep
1 Oncology (Williston Park)
9 Prostate
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. FELKER ER, Raman SS, Lu DSK, Tuttle M, et al
    Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation.
    AJR Am J Roentgenol. 2019 Jul 30:1-6. doi: 10.2214/AJR.19.21637.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. SHIOTA M, Nakamura M, Yokomizo A, Tomoda T, et al
    Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.
    Anticancer Res. 2019;39:4411-4414.
    PubMed     Text format     Abstract available

  3. SINHA AA
    Electron Microscopic Analysis of Stem Cells in Human Prostate Cancer, Including Inverted Capsule Embedding Methods for Archival Sections and Falcon Films for Prostate Cancer Cell Lines.
    Anticancer Res. 2019;39:4171-4177.
    PubMed     Text format     Abstract available


    Br J Radiol

  4. SUN Y, Williams S, Byrne D, Keam S, et al
    Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study.
    Br J Radiol. 2019 Jul 30:20190373. doi: 10.1259/bjr.20190373.
    PubMed     Text format     Abstract available


    Cancer Imaging

  5. FERREIRA G, Iravani A, Hofman MS, Hicks RJ, et al
    Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution.
    Cancer Imaging. 2019;19:23.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  6. BELTRAN H, Hruszkewycz A, Scher HI, Hildesheim J, et al
    The role of lineage plasticity in prostate cancer therapy resistance.
    Clin Cancer Res. 2019 Jul 30. pii: 1078-0432.CCR-19-1423.
    PubMed     Text format     Abstract available

  7. BHAGIRATH D, Yang TL, Tabatabai ZL, Majid S, et al
    BRN4 is a novel driver of neuroendocrine differentiation in castration-resistant prostate cancer and is selectively released in extracellular vesicles with BRN2.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-0498.
    PubMed     Text format     Abstract available


    Eur Urol

  8. WALSH PC
    Re: Association of Treatment with 5alpha-Reductase inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    Eur Urol. 2019 Jul 22. pii: S0302-2838(19)30546.
    PubMed     Text format    

  9. JEONG CW, Cowan JE, Broering JM, Ten Ham RMT, et al
    Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.
    Eur Urol. 2019 Jul 22. pii: S0302-2838(19)30536.
    PubMed     Text format     Abstract available

  10. PASCHALIS A, Sheehan B, Riisnaes R, Rodrigues DN, et al
    Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    Eur Urol. 2019 Jul 13. pii: S0302-2838(19)30520.
    PubMed     Text format     Abstract available

  11. STENZL A
    Re: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30549.
    PubMed     Text format    

  12. SIGHINOLFI MC, Rocco B
    Re: EAU Guidelines: Prostate Cancer 2019.
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30538.
    PubMed     Text format    

  13. HOFMAN MS, Emmett L
    Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?
    Eur Urol. 2019 Jul 24. pii: S0302-2838(19)30584.
    PubMed     Text format    

  14. MCLENNAN D, Sathianathen N, Alghazo O, Azad A, et al
    Re: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jul 25. pii: S0302-2838(19)30550.
    PubMed     Text format    

  15. BUTCHER G, Howard H, Sathianathen N, Catto JWF, et al
    Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2019 Jul 25. pii: S0302-2838(19)30542.
    PubMed     Text format    

  16. VAN DER POEL H
    Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.
    Eur Urol. 2019 Jul 26. pii: S0302-2838(19)30545.
    PubMed     Text format    

  17. HACKMAN G, Taari K, Tammela TL, Matikainen M, et al
    Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
    Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30525.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  18. TAPROGGE J, Murray I, Gear J, Chittenden SJ, et al
    Title: Compartmental model for (223)Ra-Dichloride in patients with metastatic bone disease from castration-resistant prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jul 23. pii: S0360-3016(19)33505.
    PubMed     Text format     Abstract available


    Int J Urol

  19. KIMURA T, Koike Y, Aikawa K, Kimura S, et al
    Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer.
    Int J Urol. 2019 Jul 28. doi: 10.1111/iju.14077.
    PubMed     Text format     Abstract available

  20. SHIGEMURA K, Fujisawa M
    Editorial Comment to Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities.
    Int J Urol. 2019 Jul 25. doi: 10.1111/iju.14085.
    PubMed     Text format    


    J Nucl Med

  21. BARNETT C, Davenport MS, Montgomery JS, Kunju LP, et al
    (18)F-choline PET/mpMRI for Detection of Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis.
    J Nucl Med. 2019 Jul 26. pii: jnumed.119.225771. doi: 10.2967/jnumed.119.225771.
    PubMed     Text format     Abstract available

  22. KRANZBUHLER B, Muller J, Becker AS, Garcia Schuler HI, et al
    Detection rate and localization of prostate cancer recurrence using (68)Ga-PSMA-11 PET/MRI in patients with low PSA values </= 0.5 ng/ml.
    J Nucl Med. 2019 Aug 2. pii: jnumed.118.225276. doi: 10.2967/jnumed.118.225276.
    PubMed     Text format     Abstract available


    J Urol

  23. CROOK J
    Editorial Comment.
    J Urol. 2019;201:1133.
    PubMed     Text format    

  24. AYDIN AM, Pow-Sang JM
    Editorial Comment.
    J Urol. 2019;201:1125-1126.
    PubMed     Text format    

  25. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:1126.
    PubMed     Text format    

  26. SIEGEL C
    Re: Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate.
    J Urol. 2019;202:190.
    PubMed     Text format    

  27. EGGENER S
    Editorial Comment.
    J Urol. 2019;202:263.
    PubMed     Text format    

  28. SANCHEZ-SALAS R, Stabile A
    Editorial Comment.
    J Urol. 2019;202:270-271.
    PubMed     Text format    

  29. PORTER CR
    Editorial Comment.
    J Urol. 2019;202:270.
    PubMed     Text format    

  30. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    Reply by Authors.
    J Urol. 2019;202:271.
    PubMed     Text format    

  31. LUIS DE CASTRO ABREU A, Jadvar H
    Editorial Comment.
    J Urol. 2019;202:420-421.
    PubMed     Text format    

  32. MOUL JW
    Editorial Comment.
    J Urol. 2019;202:254.
    PubMed     Text format    

  33. SUNDI D, Nyame YA
    Editorial Comment.
    J Urol. 2019;202:254-255.
    PubMed     Text format    

  34. OISHI M, Gill IS, Tafuri A, Shakir A, et al
    Hemi-Gland Cryoablation for Localized Low-, Intermediate- and High-Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 years.
    J Urol. 2019 Jul 26:101097JU0000000000000456. doi: 10.1097/JU.0000000000000456.
    PubMed     Text format     Abstract available

  35. JACOBS BL, Yabes JG, Lopa SH, Heron DE, et al
    The Influence of Stereotactic Body Radiation Therapy Adoption on Prostate Cancer Treatment Patterns.
    J Urol. 2019 Jul 30:101097JU0000000000000471. doi: 10.1097/JU.0000000000000471.
    PubMed     Text format     Abstract available

  36. ATALA A
    Re: ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jul 31:10109701JU000057944436265.
    PubMed     Text format    


    Nat Rev Urol

  37. THARMALINGAM H, Choudhury A, Van Herk M, McWilliam A, et al
    New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer.
    Nat Rev Urol. 2019 Jul 25. pii: 10.1038/s41585-019-0213.
    PubMed     Text format     Abstract available


    Oncol Rep

  38. TANG C, Liu T, Wang K, Wang X, et al
    Transcriptional regulation of FoxM1 by HIF1alpha mediates hypoxiainduced EMT in prostate cancer.
    Oncol Rep. 2019 Jul 25. doi: 10.3892/or.2019.7248.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  39. KITTLES R
    Addressing the Disparities in Prostate Cancer Care and Outcomes.
    Oncology (Williston Park). 2019;33.
    PubMed     Text format    


    Prostate

  40. HELLSTEN R, Lilljebjorn L, Johansson M, Leandersson K, et al
    The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors.
    Prostate. 2019 Jul 26. doi: 10.1002/pros.23885.
    PubMed     Text format     Abstract available

  41. FU S, Wan X, Du C, Wang H, et al
    A novel fluorescent probe for the early detection of prostate cancer based on endogenous zinc sensing.
    Prostate. 2019;79:1378-1385.
    PubMed     Text format     Abstract available

  42. PALLER CJ, Piana D, Eshleman JR, Riel S, et al
    A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
    Prostate. 2019 Jul 30. doi: 10.1002/pros.23883.
    PubMed     Text format     Abstract available

  43. CHENG A, Zhao S, FitzGerald LM, Wright JL, et al
    A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23882.
    PubMed     Text format     Abstract available

  44. TANAKA M, Kimura T, Iwamura Y, Enei Y, et al
    No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23884.
    PubMed     Text format     Abstract available

  45. WANG J, Xu W, Mierxiati A, Huang Y, et al
    Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23878.
    PubMed     Text format     Abstract available

  46. EICH ML, Chandrashekar DS, Rodriguez Pen A MDC, Robinson AD, et al
    Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23887.
    PubMed     Text format     Abstract available

  47. KAIPAINEN A, Zhang A, Gil da Costa RM, Lucas J, et al
    Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23874.
    PubMed     Text format     Abstract available

  48. MEUNIER ME, Tantot J, Neuzillet Y, Ghoneim TP, et al
    Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23888.
    PubMed     Text format     Abstract available


    Radiology

  49. SCIALPI M, Scialpi P, Aisa MC, Martorana E, et al
    Simplified PI-RADS with Biparametric MRI: A Practical Approach to Improve Management of PI-RADS Version 2 Category 3 Lesions.
    Radiology. 2018 Nov 6:182092. doi: 10.1148/radiol.2018182092.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: